Ossifying synovial sarcoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 4. JTCVS Open. 2022 Feb 24;10:404-414. doi: 10.1016/j.xjon.2022.02.014. eCollection 2022 Jun. Primary pulmonary synovial sarcoma. Wang W(1), Guo J(2), Bao M(3), Liu X(3), Wang H(3), Ye C(3). Author information: (1)Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China. (2)Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. (3)Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. OBJECTIVE: Primary pulmonary synovial sarcoma (PPSS) is extremely rare. This study aims to identify the clinicopathologic and therapeutic factors determining survival in PPSS. METHODS: We performed a retrospective analysis of 121 patients from the Surveillance, Epidemiology, and End Results Database as well as 12 patients from our own institution diagnosed with PPSS. Patient survival was evaluated using the Kaplan-Meier method. RESULTS: The median survival time for 12 PPSS patients in our institution was 78 months. Postoperative chemotherapy (P = .027 for overall survival and P = .035 for disease-specific survival) was associated with superior survival, whereas pneumonectomy (P = .011 for overall survival and P = .006 for disease-specific survival) was associated with worse survival. Single lobe involvement (P = .022) and the absence of lymph node involvement (P = .045) were associated with improved disease-specific survival and overall survival, respectively. In the Surveillance, Epidemiology, and End Results Database, the median survival time was 23 months. Significantly superior survival was observed in patients with earlier American Joint Committee on Cancer stage (Ⅰ-Ⅱ) (P